{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:09:24Z","timestamp":1791050964463,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.clinthera.2011.11.004","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T08:58:55Z","timestamp":1323853135000},"page":"2060-2070","source":"Crossref","is-referenced-by-count":39,"title":["Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"chictr-rnc-11001342","registry":"10.18810\/chictr"}],"author":[{"given":"Guoping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.11.004_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.tpj.6500144","article-title":"Cytochrome P450 3A pharmacogenetics: the road that needs traveled","volume":"3","author":"Flockhart","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clinthera.2011.11.004_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2011.11.004_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17425255.2.2.171","article-title":"Clinical implications of CYP3A polymorphisms","volume":"2","author":"Wojnowski","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2011.11.004_bib4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2011.11.004_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1289\/ehp.0800528","article-title":"Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine","volume":"117","author":"Chen","year":"2009","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.clinthera.2011.11.004_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1124\/dmd.32.1.149","article-title":"Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter\/enhancer region","volume":"32","author":"Koyano","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.11.004_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1389200054633880","article-title":"Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics","volume":"6","author":"Lamba","year":"2005","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2011.11.004_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2005.05.011","article-title":"Functional analysis of four naturally occurring variants of human constitutive androstane receptor","volume":"86","author":"Ikeda","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2011.11.004_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clpt.2005.11.013","article-title":"MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype","volume":"79","author":"Lamba","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.11.004_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.fpc.0000114744.08559.92","article-title":"Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)","volume":"14","author":"Letschert","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib12","doi-asserted-by":"crossref","first-page":"43058","DOI":"10.1074\/jbc.M207735200","article-title":"A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter","volume":"277","author":"Michalski","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.11.004_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1124\/jpet.302.2.804","article-title":"Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis","volume":"302","author":"Nozawa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.11.004_bib14","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.11.004_bib15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1073\/pnas.0711621105","article-title":"Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations","volume":"105","author":"Huang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2011.11.004_bib16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2006-2345","article-title":"Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency","volume":"92","author":"Scott","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2011.11.004_bib17","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1021\/bi001718u","article-title":"Determination of the redox properties of human NADPH-cytochrome P450 reductase","volume":"40","author":"Munro","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.clinthera.2011.11.004_bib18","doi-asserted-by":"crossref","first-page":"29163","DOI":"10.1074\/jbc.M101731200","article-title":"NADPH-cytochrome P450 oxidoreductase","volume":"276","author":"Hubbard","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.11.004_bib19","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1073\/pnas.94.16.8411","article-title":"Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2011.11.004_bib20","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1210\/en.2005-0096","article-title":"Minireview: regulation of steroidogenesis by electron transfer","volume":"146","author":"Miller","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2011.11.004_bib21","doi-asserted-by":"crossref","first-page":"25895","DOI":"10.1074\/jbc.M303125200","article-title":"Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase","volume":"278","author":"Gu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.11.004_bib22","doi-asserted-by":"crossref","first-page":"13480","DOI":"10.1074\/jbc.M212087200","article-title":"Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase","volume":"278","author":"Henderson","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.11.004_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1086\/429417","article-title":"Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis","volume":"76","author":"Huang","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2011.11.004_bib24","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1210\/jc.2008-0304","article-title":"The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency","volume":"93","author":"Gomes","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2011.11.004_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.09.7","article-title":"Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation","volume":"10","author":"Gomes","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32830054ac","article-title":"Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19","volume":"18","author":"Agrawal","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","article-title":"The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test","volume":"19","author":"Oneda","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2008.292","article-title":"Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis","volume":"5","author":"McConn","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.11.004_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-6-19","article-title":"CYP3A4 and CYP3A5 genotyping by Pyrosequencing","volume":"6","author":"Garsa","year":"2005","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.clinthera.2011.11.004_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00228-004-0767-7","article-title":"Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.11.004_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-200404000-00005","article-title":"CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene","volume":"14","author":"Eap","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1570-0232(02)00673-6","article-title":"Determination of midazolam and 1\u2032-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment","volume":"783","author":"Shiran","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2011.11.004_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clpt.2006.09.009","article-title":"Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects","volume":"80","author":"Kim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.11.004_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.chroma.2003.12.039","article-title":"Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry","volume":"1031","author":"Kanazawa","year":"2004","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.clinthera.2011.11.004_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/14622416.8.5.443","article-title":"Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes","volume":"8","author":"Schirmer","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2011.11.004_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2011.11.004_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.11.004_bib39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/00498250903226025","article-title":"Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients","volume":"39","author":"Chen","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2011.11.004_bib40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00228-009-0619-6","article-title":"Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort","volume":"65","author":"Zhao","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.11.004_bib41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/FPC.0b013e32833e0cb5","article-title":"Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase","volume":"20","author":"Agrawal","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2011.11.004_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1440-1681.2007.04691.x","article-title":"Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum","volume":"34","author":"Canaparo","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T21:26:17Z","timestamp":1713216377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811007211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0149291811007211"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.11.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}